Search

Displaying results 5961 - 5970 of 10000 in total
  1. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever. … The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of <i>S. typhi</i>. It is being developed by AVANT Immunotherapeutics, Inc.

  2. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.

  3. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. … XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models.

  4. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA.

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. … This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.

  6. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

    Categories: Heterocyclic Compounds, 2-Ring, Bradykinin Receptor Antagonists
  7. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  8. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract.

  10. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. … It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication